Biomarker NTRK Coverage from Every Angle
Advertisement
Advertisement

Gregory J. Riely, MD, PhD, on the Clinical Impact of Targeting NTRK Gene Fusion in Advanced Cancers

Posted: Wednesday, September 1, 2021

Gregory J. Riely, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the dramatic changes in the way patients with advanced tumors are treated, the impact of NTRK fusions, and the drugs that can target them. Dr. Riely specifically focused on non–small cell lung cancer, where some of the greatest advances have occurred, thanks to long-lasting responses to targeted therapies for ALK fusions and EGFR mutations.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.